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The immunoglobulin G (IgG) subclass distribution of antibodies to merozoite surface antigen 2 of Plasmo-
dium falciparum in Solomon Islanders showed marked skewing towards the IgG3 subclass. This was not
observed with crude P. falciparum schizont antigen. IgG3 responses may be short-lived and require repeated
restimulation for their maintenance. This may be provided by persistent infection (premunition) or new
infections.
Several antigens of asexual blood-stage Plasmodium falcipa-
rum have been identified as vaccine candidates because of their
ability to protect against malaria in animal model systems
and/or because antibodies to them inhibit parasite multiplica-
tion in vitro (14). Identifying the immune responses to such
“protective” antigens following natural infections can aid un-
derstanding of the host-parasite relationship and provide in-
formation beneficial to the development of malaria vaccines.
We have had a long-term interest in merozoite surface antigen
2 (MSA2; also called merozoite surface protein 2) of P. falci-
parum (19, 20). MSA2 has undergone a phase I clinical trial
(22) and is undergoing further phase I testing in preparation
for a phase 2 trial. There are two major allelic families of this
antigen, represented by the parasite strains FCQ-27 and 3D7.
Immunity based on MSA2 can be envisaged to involve anti-
bodies or antibody-mediated mechanisms (5, 12, 15).
Isotype or subclass specificities of antibodies elicited to de-
fined malarial antigens can be expected to have a marked bear-
ing on the effectiveness of the immune response. Immunoglob-
ulin G1 (IgG1) and IgG3 subclass antibodies are cytophilic
and show extensive complement fixing ability. They promote
phagocytosis, antibody-dependent cell-mediated cytotoxicity,
and antibody-dependent cellular inhibition (ADCI); this is not
the case with IgG2 or IgG4 antibodies, which are not cytophilic
or complement fixing. Indeed, IgG2 or IgG4 may adversely
affect these mechanisms by competing with IgG1 and IgG3 for
the antigen (5, 10). In Thai adults infected with P. falciparum,
the predominance of antimalarial antibodies of the IgG1 and
IgG3 subclasses was associated with protection whereas a pre-
dominance of IgG2 and IgG4 subclasses or IgM or low levels
of antibodies were associated with susceptibility (5). Sera from
protected individuals mediated ADCI in vitro (5). Elevated
levels of malaria-specific IgE antibodies have been detected in
the sera of Papua New Guineans, Africans, and Asians (16).
The significance of these IgE antibodies is unclear. There is no
evidence that such antibodies are protective.
A high proportion of villagers in the Solomon Islands and in
Papua New Guinea (PNG), where P. falciparum is prevalent,
have antibodies to MSA2 (2, 20). This study presents data on
the distribution of IgG subclass antibodies to the FCQ-27 and
3D7 forms of the MSA2 protein. Both these allelic forms occur
in PNG (8) and the Solomon Islands (17).
Sera were collected with informed consent from villagers (14
to 48 years old) living in Guadalcanal, Solomon Islands. Anti-
bodies of the various IgG subclasses were measured by en-
zyme-linked immunosorbent assay (7, 9). Antigens used were
(i) a recombinant MSA2 (r-MSA2) protein with the 3D7
sequence (22), (ii) a comparable r-MSA2 protein with the
FCQ-27 sequence (22), and (iii) a crude antigen preparation of
late-asexual-stage P. falciparum parasites (schizont antigen)
made by repeated freeze-thawing of schizont- and late-tropho-
zoite-enriched cultures of the FCQ-27 strain. Flat-bottomed
microtiter plates were coated with 2 mg of r-MSA2 protein
(FCQ-27 or 3D7) per ml or with schizont antigen equivalent to
5 3 104 parasites/well. After overnight incubation at 48C, wells
were washed with phosphate-buffered saline–Tween, and then
twofold dilutions of the human serum samples were added
before a further overnight incubation at 48C. After being
washed, plates were incubated with monoclonal antibody to
either IgG1 (NL-16; Oxoid, Basingstoke, Hampshire, United
Kingdom), IgG2 (HP6014; Sigma Chemical Co., St. Louis,
Mo.), IgG3 (SJ33; Sigma Chemical Co.), or IgG4 (SK44; Bio-
makor, Rehovot, Israel). The antisubclass antibodies were se-
lected for their high affinity and because they were not re-
stricted to specific allotypes (7, 9). After incubation for 3 h
at 378C, affinity-purified sheep anti-mouse immunoglobulin
tagged with horseradish peroxidase conjugate was added. The
plates were further incubated at 378C for 1 h, and after a wash-
ing, 10 ml of the substrate ABTS (2,2-azino-di [3-ethylbenz-
thiazolone sulfanate-6) (Boehringer, Mannheim, Germany)
was added. The absorption was read at 410 nm following a 1-h
incubation at 378C. The enzyme-linked immunosorbent assay
endpoint titer for each serum was defined as the reciprocal
dilution corresponding to half the value of the difference be-
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tween the highest optical density (OD) value for the serum and
the baseline value. The baseline value was the OD value ob-
tained with pooled sera from healthy Australians with no his-
tory of malaria exposure at a dilution of 1/100. Baseline OD
values between 0.065 to 0.08 were obtained. OD values for
Solomon Island sera with the highest titers were either slightly
above or slightly below 2.0.
We found that a high proportion of the Solomon Island sera
contained antibodies to MSA2, which is consistent with previ-
ous findings (20). Of the 20 sera examined for IgG subclass
antibodies to the FCQ-27 form of MSA2, all had titers of.100
for at least one of the four subclasses measured and 17 showed
titers of .500. Comparable analyses with the 3D7 MSA2
found that 48 of 52 serum samples had titers of.100 and 21 of
these had titers of .500. A striking feature of these analyses
was the predominance of IgG3 antibodies, with antibodies to
IgG1, IgG2, and IgG4 being only minor components of the
response (Table 1). In all instances except one (namely, a
serum sample with a low-titer anti-3D7 MSA2 response), the
titers for IgG3 were found to exceed those for IgG1, which was
unexpected under the conditions of repeated exposure to the
parasite that occur in the Solomon Islands (11, 13). This is
highlighted in Table 2, where individual titers for IgG1 and
IgG3 antibodies to FCQ-27 MSA2 are presented for the 20
subjects screened. In contrast, IgG antibody responses to the
FCQ-27 schizont antigen in the same population gave a more
expected subclass distribution, with IgG1 and IgG3 subclasses
dominant and with an increased representation of IgG2 and
IgG4 antibodies (Table 1).
Skewing of the IgG antibody subclass response to MSA2
towards IgG3 has also been reported in the Gambia, where
malaria transmission is seasonal (24). Thus, the IgG3 bias is
seen in geographically widely separated populations of differ-
ent ethnic backgrounds. It was concluded in the Gambian
study that the anti-MSA2 IgG3 may be a very effective anti-
parasite response because these antibodies are cytophilic and
complement fixing and may also be able to block the invasion
of merozoites into erythrocytes. Such a view is consistent with
the data from PNG in which antibodies to MSA2 were asso-
ciated with protection (2).
The predominance of antibodies of the IgG3 subclass sug-
gests that there may be a defect in the downstream switching of
the antibody response to IgG1. IgG1 and IgG3, while similar in
their functional characteristics, differ in that IgG1 responses
persist for longer periods whereas IgG3 responses are normally
transient (10). We have proposed that while antibodies of the
IgG3 subclass may be efficient in clearing parasites, their ef-
fectiveness may be limited in situations where boosting is in-
frequent because they are unlikely to persist (13). Hence, in
areas such as PNG and the Solomon Islands, where malaria
transmission rates are among the highest in the world and
transmission occurs year-round, repeated reexposure to the
antigen would ensure that the IgG3 antibody responses are
maintained and immunity dependent on these antibodies is not
impaired. However, in situations where transmission is inter-
rupted, e.g., in areas of seasonal transmission or in association
with migration away from areas of endemicity, it might be
expected that IgG3 antibodies to MSA2 would rapidly wane,
and this may compromise host immunity if MSA2, as is be-
lieved, is a target of protective immunity.
Based on our proposal, in the Gambia, where malaria is
seasonal, IgG3 titers should wane in the dry season, when
transmission is minimal. While this has not yet been directly
addressed, recently published findings from the Gambia (23)
showed that total IgG antibodies to MSA2 (taken here to be
mostly IgG3 according to previous Gambian data [24]) did not
significantly fluctuate between transmission seasons in clini-
cally immune adults, although there was evidence that seasonal
fluctuations in antibody levels consistent with malaria trans-
mission were evident in semi-immune children.
The findings in adults, which appear to be inconsistent with
our original proposal that IgG3 antibodies will wane in areas of
seasonal transmission, could be explained if it were to be dem-
onstrated that there is chronic persistence of low-grade para-
sitemias in this clinically immune group of adults in the Gam-
bia and that these parasites provide the boosting necessary to
maintain the IgG3 antibody levels. We consider that persis-
tence of parasites through at least part of the dry season is very
likely to occur in the Gambia based on other data. For in-
stance, by using sensitive PCR technology in addition to mi-
croscopy, the persistence of parasites asymptomatically in in-
dividuals for several months in the dry season, often as
multiclonal infections, has been shown in Sudan (3). Other
recent research also supports the idea of malaria chronicity (4,
18).
Premunition, also known as concomitant immunity, is char-
acterized by an equilibrium in the host-parasite response with
the parasite not eliminated but persisting at low densities and
conferring some protection against subsequent infections (1, 6,
21). This immune state may well provide a mechanism by
which immunity dependent on IgG3 subclass responses may be
maintained. Premunition has been reported to be IgG depen-
dent, with the IgG proposed to mediate ADCI, which requires
cytophilic antibodies like IgG3 (6). Moreover, premunition
TABLE 1. Endpoint titers of IgG subclass antibodies to malarial
antigens in the sera of Solomon Islanders
Antigen
No. of
serum
samples
Antibody titer (mean 6 SE)
IgG1 IgG2 IgG3 IgG4
r-MSA2 (3D7) 52 2266 53 63 6 9 960 6 107 52 6 8
r-MSA2 (FCQ-27) 20 3766 83 201 6 52 4,968 6 994 160 6 17
Schizont (FCQ-27) 20 1,9986 362 614 6 101 1,651 6 431 905 6 215
TABLE 2. Comparison of IgG1 and IgG3 endpoint antibody
titers to r-MSA2 (FCQ-27) in individuals
Serum
sample no.
Antibody titer
IgG1 IgG3
1 99 8,000
2 234 2,435
3 308 7,192
4 103 522
5 757 5,367
6 816 11,504
7 114 234
8 84 488
9 191 1,818
10 282 4,098
11 438 12,800
12 156 472
13 403 1,368
14 1,600 9,564
15 873 12,800
16 214 4,583
17 237 970
18 92 469
19 290 691
20 312 8,288
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appears to be independent of transmission levels provided that
transmission occurs at least once per year (6).
The findings that there were seasonal fluctuations in anti-
MSA2 antibody titers in children in the Gambia (23) are con-
sistent with our expectations (13). However, observed differ-
ences between children and adults in the Gambia have yet to
be explained. A possible answer is that the semi-immune chil-
dren may have required and received treatment for their ma-
laria infections. Treatment with the consequent loss of para-
sites would then be reflected in a sharp decline in antibody
levels, as we have proposed and as was observed. It may also be
that semi-immune children have not yet developed immune
responses leading to a state of premunition (6), which may be
necessary for the maintenance of the IgG3 antibodies in the
absence of new infections.
To evaluate further the in vivo significance of our findings, it
will be important both to demonstrate directly that anti-MSA2
IgG3 titers wane rapidly in the absence of regular boosting,
either as a result of new infections or by chronic infections, and
to compare responses in children and in adults. It will be also
important to determine whether the atypical subclass distribu-
tion seen with MSA2 is also manifested with other antigens
and whether there is any evidence that such abnormal antibody
responses are preferentially associated with antigens which are
considered targets of protective immunity. We believe that our
findings have potentially important implications for vaccines
based on MSA2 and possibly other malarial antigens since
induction by vaccination of antibodies primarily comprised of
IgG3 may provide only short-term protection if mechanisms
for regular boosting of these responses are not in place.
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